Comparative Pharmacology
Head-to-head clinical analysis: PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE versus TAVIST 1.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE versus TAVIST 1.
PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE vs TAVIST-1
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenylephrine is a selective alpha-1 adrenergic receptor agonist causing vasoconstriction; promethazine is a phenothiazine derivative that blocks histamine H1 receptors and has anticholinergic, antiemetic, and sedative effects.
TAVIST-1 (clemastine fumarate) is a first-generation antihistamine that acts as a competitive antagonist at histamine H1 receptors, thereby preventing histamine-mediated effects such as vasodilation, increased capillary permeability, and bronchoconstriction. It also exhibits anticholinergic and sedative properties.
IV: 0.1-0.5 mg phenylephrine and 12.5-25 mg promethazine as a single dose.
1.34 mg orally twice daily; maximum 8.04 mg/day.
None Documented
None Documented
Phenylephrine: 2-3 hours (terminal). Promethazine: 10-14 hours (terminal in adults; prolonged in elderly and hepatic impairment).
Terminal half-life 12–15 hours; clinical dosing interval every 12 hours.
Phenylephrine: renal (80% as unchanged drug and sulfate conjugates). Promethazine: renal (70-80% as metabolites and unchanged drug), fecal (20-30%).
Primarily renal: ~60% unchanged; biliary/fecal: ~30% as metabolites; minor via feces.
Category A/B
Category C
Antihistamine / Antiemetic
Antihistamine